| Primary |
| Multiple Sclerosis |
81.3% |
| Gait Disturbance |
6.3% |
| Balance Disorder |
3.1% |
| Muscle Spasticity |
3.1% |
| Product Used For Unknown Indication |
3.1% |
| Urinary Tract Infection |
3.1% |
|
| Urinary Tract Infection |
11.5% |
| Death |
7.7% |
| Metrorrhagia |
7.7% |
| Vertebral Foraminal Stenosis |
7.7% |
| Wound |
7.7% |
| Colitis |
3.8% |
| Insomnia |
3.8% |
| Localised Infection |
3.8% |
| Monocyte Count Increased |
3.8% |
| Musculoskeletal Stiffness |
3.8% |
| Myoclonus |
3.8% |
| Spinal Laminectomy |
3.8% |
| Suicide Attempt |
3.8% |
| Traumatic Intracranial Haemorrhage |
3.8% |
| Tremor |
3.8% |
| Upper Limb Fracture |
3.8% |
| Venous Injury |
3.8% |
| Ventricular Extrasystoles |
3.8% |
| Visual Field Defect |
3.8% |
| Vomiting |
3.8% |
|
| Secondary |
| Multiple Sclerosis |
53.1% |
| Gait Disturbance |
14.3% |
| Product Used For Unknown Indication |
5.1% |
| Balance Disorder |
4.1% |
| Relapsing-remitting Multiple Sclerosis |
4.1% |
| Muscle Spasticity |
3.1% |
| Pain |
3.1% |
| Urinary Tract Infection |
3.1% |
| Blood Pressure |
2.0% |
| Back Pain |
1.0% |
| Blood Cholesterol Increased |
1.0% |
| Depression |
1.0% |
| Fatigue |
1.0% |
| Movement Disorder |
1.0% |
| Muscle Relaxant Therapy |
1.0% |
| Platelet Aggregation Inhibition |
1.0% |
| Trigeminal Neuralgia |
1.0% |
|
| Convulsion |
12.5% |
| Tremor |
12.5% |
| Fatigue |
9.4% |
| Alanine Aminotransferase Increased |
6.3% |
| Arrhythmia |
6.3% |
| Loss Of Consciousness |
6.3% |
| Myoclonus |
6.3% |
| Abdominal Discomfort |
3.1% |
| Abdominal Pain Upper |
3.1% |
| Asthenia |
3.1% |
| Balance Disorder |
3.1% |
| Blood Albumin Decreased |
3.1% |
| Blood Alkaline Phosphatase Increased |
3.1% |
| Central Nervous System Lesion |
3.1% |
| Dizziness |
3.1% |
| Dry Mouth |
3.1% |
| Feeling Abnormal |
3.1% |
| Gait Disturbance |
3.1% |
| Grand Mal Convulsion |
3.1% |
| Head Injury |
3.1% |
|
| Concomitant |
| Multiple Sclerosis |
55.2% |
| Relapsing-remitting Multiple Sclerosis |
9.5% |
| Product Used For Unknown Indication |
6.1% |
| Gait Disturbance |
5.7% |
| Hypertension |
3.8% |
| Depression |
3.0% |
| Bladder Disorder |
2.7% |
| Muscle Spasms |
2.5% |
| Muscle Spasticity |
1.8% |
| Dyspepsia |
1.1% |
| Hyperthyroidism |
1.1% |
| Prophylaxis |
1.1% |
| Fatigue |
0.9% |
| Nausea |
0.9% |
| Premedication |
0.9% |
| Walking Disability |
0.9% |
| Constipation |
0.7% |
| Insomnia |
0.7% |
| Pain |
0.7% |
| Pain Prophylaxis |
0.7% |
|
| Confusional State |
11.7% |
| White Blood Cell Count Decreased |
7.8% |
| Alanine Aminotransferase Increased |
6.8% |
| Death |
6.8% |
| Fall |
5.8% |
| Multiple Sclerosis |
5.8% |
| Multiple Sclerosis Relapse |
5.8% |
| Diarrhoea |
4.9% |
| Visual Acuity Reduced |
4.9% |
| Blood Pressure Increased |
3.9% |
| Lymphocyte Count Decreased |
3.9% |
| Nausea |
3.9% |
| Neutrophil Count Increased |
3.9% |
| Oedema Peripheral |
3.9% |
| Syncope |
3.9% |
| Vision Blurred |
3.9% |
| Vomiting |
3.9% |
| Asthenia |
2.9% |
| Back Pain |
2.9% |
| Balance Disorder |
2.9% |
|
| Interacting |
| Multiple Sclerosis |
48.1% |
| Sleep Disorder |
14.8% |
| Anxiety |
7.4% |
| Depression |
7.4% |
| Gait Disturbance |
7.4% |
| Muscle Spasticity |
7.4% |
| Paraparesis |
7.4% |
|
| Palpitations |
40.0% |
| Depression |
20.0% |
| Grimacing |
20.0% |
| Urinary Tract Infection |
20.0% |
|
